drugset / Trial / NCT02025608
Autonomic Function and Cardiovascular Risk in Restless Legs Syndrome
Phase 4
Completed
20 enrolled
Mauro Manconi
Cardiocentro Ticino · collabInsel Gruppe AG, University Hospital Bern · collab
RandomizedParallel-groupQuadruple-blindOther
Summary
The purpose of this study is to explore whether patients with restless legs syndrome (RLS) differ from healthy subjects in daytime and night time autonomic function and cardiovascular risk markers and whether 4 week treatment with pramipexole affects autonomic function and cardiovascular risk markers in patients with RLS.
Timeline
- Start
- 2013-12
- Primary completion
- 2016-12-31
- Completion
- 2016-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pramipexole | Unknown | 0.25 mg | — |